Human Phospho-Insulin R (Y1162/Y1163)/
IGF-I R (Y1135/Y1136) Antibody

Detection of Human Human Phospho-Insulin R (Y1162/Y1163)/ IGF-I R (Y1135/Y1136) Antibody by Immunohistochemistry

Eighty-seven percent of patients with invasive breast cancer have activated Insulin/IGF1 receptors. a Immunohistochemical staining of invasive breast cancer tissue serial sections stained for phospho-Insulin/IGF1 receptor and CD163. Scale bars, 100 μm and 50 μm. b Upper diagram: Pie diagram representing the percentage of phospho-Insulin/IGF1 receptor positive (red) and negative (green) tumors assessed in tissue microarray (TMA) containing biopsies from 90 consented patients with invasive breast cancer. Lower diagrams: represent the percentage of phospho-Insulin/IGF1 receptor positive (red) and negative (green) tumors of the molecular subsets, TNBC, HR+, and HER2+. c Expression levels of Igf-1, Igf-2, cd163, and mrc1 associated with survival in breast cancer patients Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29367764), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human Human Phospho-Insulin R (Y1162/Y1163)/ IGF-I R (Y1135/Y1136) Antibody by Immunohistochemistry

75% of breast cancer patients have activated Insulin/IGF1 receptors and Insulin/IGF-1 receptor activation positively correlates with macrophage infiltration and advanced tumor stage. a Serial sections of biopsies from non-malignant breast tissue immunohistochemically stained for phospho-Insulin/IGF1 receptor, CD163 and CD68. Scale bars, 100 μm and 50 μm. b and c Serial sections of biopsies from breast cancer patients immunohistochemically stained for phospho-insulin/IGF1 receptor, CD163, and CD68. Scale bars, 100 μm and 50 μm. d Bar graph depicting the quantification of CD68 and CD163 positive macrophages in non-malignant breast tissue and breast cancer tissue samples. Error bars represent s.d. (n = 3); * two-tailed p-value ≤ 0.05, *** two-tailed p-value ≤ 0.005 using a student’s t-test. e Pie diagram representing the percentage of phospho-Insulin/IGF-1 receptor positive (red) and negative (green) tumors assessed in a tissue microarray containing biopsies from 75 breast cancer patients. f Contingency table and results from statistical analysis showing a positive correlation between phospho-Insulin/IGF-1 receptor expression in breast tumors and increased CD163+ macrophage infiltration. Chi-square = 4.37; p = 0.04. g Contingency table and results from statistical analysis showing a positive correlation between phospho-Insulin/IGF1 receptor and CD163+ macrophages co-expression and tumor stage. Chi-square = 4.89; p = 0.03 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29367764), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human Human Phospho-Insulin R (Y1162/Y1163)/ IGF-I R (Y1135/Y1136) Antibody by Immunohistochemistry

75% of breast cancer patients have activated Insulin/IGF1 receptors and Insulin/IGF-1 receptor activation positively correlates with macrophage infiltration and advanced tumor stage. a Serial sections of biopsies from non-malignant breast tissue immunohistochemically stained for phospho-Insulin/IGF1 receptor, CD163 and CD68. Scale bars, 100 μm and 50 μm. b and c Serial sections of biopsies from breast cancer patients immunohistochemically stained for phospho-insulin/IGF1 receptor, CD163, and CD68. Scale bars, 100 μm and 50 μm. d Bar graph depicting the quantification of CD68 and CD163 positive macrophages in non-malignant breast tissue and breast cancer tissue samples. Error bars represent s.d. (n = 3); * two-tailed p-value ≤ 0.05, *** two-tailed p-value ≤ 0.005 using a student’s t-test. e Pie diagram representing the percentage of phospho-Insulin/IGF-1 receptor positive (red) and negative (green) tumors assessed in a tissue microarray containing biopsies from 75 breast cancer patients. f Contingency table and results from statistical analysis showing a positive correlation between phospho-Insulin/IGF-1 receptor expression in breast tumors and increased CD163+ macrophage infiltration. Chi-square = 4.37; p = 0.04. g Contingency table and results from statistical analysis showing a positive correlation between phospho-Insulin/IGF1 receptor and CD163+ macrophages co-expression and tumor stage. Chi-square = 4.89; p = 0.03 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29367764), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human Human Phospho-Insulin R (Y1162/Y1163)/ IGF-I R (Y1135/Y1136) Antibody by Immunohistochemistry

Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm2, twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel (n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29367764), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human Human Phospho-Insulin R (Y1162/Y1163)/ IGF-I R (Y1135/Y1136) Antibody by Immunohistochemistry

75% of breast cancer patients have activated Insulin/IGF1 receptors and Insulin/IGF-1 receptor activation positively correlates with macrophage infiltration and advanced tumor stage. a Serial sections of biopsies from non-malignant breast tissue immunohistochemically stained for phospho-Insulin/IGF1 receptor, CD163 and CD68. Scale bars, 100 μm and 50 μm. b and c Serial sections of biopsies from breast cancer patients immunohistochemically stained for phospho-insulin/IGF1 receptor, CD163, and CD68. Scale bars, 100 μm and 50 μm. d Bar graph depicting the quantification of CD68 and CD163 positive macrophages in non-malignant breast tissue and breast cancer tissue samples. Error bars represent s.d. (n = 3); * two-tailed p-value ≤ 0.05, *** two-tailed p-value ≤ 0.005 using a student’s t-test. e Pie diagram representing the percentage of phospho-Insulin/IGF-1 receptor positive (red) and negative (green) tumors assessed in a tissue microarray containing biopsies from 75 breast cancer patients. f Contingency table and results from statistical analysis showing a positive correlation between phospho-Insulin/IGF-1 receptor expression in breast tumors and increased CD163+ macrophage infiltration. Chi-square = 4.37; p = 0.04. g Contingency table and results from statistical analysis showing a positive correlation between phospho-Insulin/IGF1 receptor and CD163+ macrophages co-expression and tumor stage. Chi-square = 4.89; p = 0.03 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29367764), licensed under a CC-BY license. Not internally tested by R&D Systems.